Exelixis’s Cabometyx Phase III trial sparks hope for pancreatic NET patients
On 24 August, Exelixis announced the early suspension of the double-blinded Phase III CABINET pivotal trial evaluating Exelixis’s Cabometyx (cabozantinib) for patients with progressive, well-differentiated […]
Exelixis’s Cabometyx Phase III trial sparks hope for pancreatic NET patients Read More »












